ijms-logo

Journal Browser

Journal Browser

Functional and Regulatory Cancer Genomics

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Genetics and Genomics".

Deadline for manuscript submissions: 31 July 2026 | Viewed by 687

Special Issue Editor


E-Mail Website
Guest Editor
Cancer Genetics, Genomics and Systems Biology Laboratory, Basic and Translational Cancer Research Center (BTCRC), Nicosia 1516, Cyprus
Interests: cancer genomics; precision medicine; data science in genomics; next-generation sequencing; translational oncology; tumor immunology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Functional and regulatory genomics has become central to understanding cancer initiation, progression, and therapeutic response. This Special Issue focuses on advances that elucidate how genomic, epigenomic, and transcriptomic alterations shape cancer phenotypes and regulatory networks across tumor types. Topics of interest include gene regulation and chromatin organization, enhancer–promoter interactions, non‑coding RNAs, transcriptional and epigenetic dysregulation, and the functional consequences of somatic and germline variants. Emphasis is placed on integrative approaches such as next‑generation sequencing, single‑cell and spatial genomics, CRISPR‑based functional screens, and multi‑omics analyses that connect genomic alterations with biological function. Contributions addressing tumor heterogeneity, cancer evolution, immune interactions, and translational applications—including biomarker discovery and precision oncology—are particularly encouraged. By bringing together original research and authoritative reviews, this Special Issue aims to provide mechanistic insights into cancer genomics and highlight emerging regulatory principles with potential clinical relevance.

Dr. Apostolos Zaravinos
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer genomics
  • functional genomics
  • regulatory genomics
  • epigenetics
  • transcriptomics
  • non‑coding RNAs
  • single‑cell genomics
  • multi‑omics
  • tumor heterogeneity
  • precision oncology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 722 KB  
Article
Impact of Pharmacogenetic Markers on the Efficacy of Neoadjuvant FLOT Chemotherapy in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma
by Denis Fedorinov, Vladimir Lyadov, Marina Lyadova, Sherzod Abdullaev, Anastasia Kachanova, Anna Filatova, Dmitriy Ivashchenko and Dmitry Sychev
Int. J. Mol. Sci. 2026, 27(9), 4114; https://doi.org/10.3390/ijms27094114 - 4 May 2026
Viewed by 405
Abstract
Despite the adoption of neoadjuvant FLOT chemotherapy as standard treatment for locally advanced gastric and gastroesophageal junction cancer, many patients fail to achieve meaningful pathological response, limiting efficacy. The aim of this study was to evaluate the impact of pharmacogenetic markers on pathological [...] Read more.
Despite the adoption of neoadjuvant FLOT chemotherapy as standard treatment for locally advanced gastric and gastroesophageal junction cancer, many patients fail to achieve meaningful pathological response, limiting efficacy. The aim of this study was to evaluate the impact of pharmacogenetic markers on pathological response in Russian patients receiving neoadjuvant FLOT. Thirty patients with locally advanced gastric or gastroesophageal junction adenocarcinoma received neoadjuvant FLOT followed by surgery. Polymorphisms in CYP3A5 (rs776746), CYP2C8 (rs10509681, rs11572080, rs1058930), ERCC1 (rs11615), and GSTP1 (rs1695) were analyzed. Favorable pathological response (TRG0-2) was observed in 23.3% of patients, including 3.3% complete responses. Most patients (76.7%) had minimal or no regression (TRG3-5). Clinical variables were not associated with response. ERCC1 (rs11615) showed a significant association: patients with the Wt/Wt genotype had higher odds of achieving TRG0-2 (OR = 8.889; p = 0.033; 95% CI: 1.294–61.058). No associations were found for CYP3A5, CYP2C8, or GSTP1. Median PFS was 18.21 months in TRG3-5, while not reached in TRG0-2 (p = 0.108). No significant PFS differences by ERCC1 genotype were observed (p = 0.525). ERCC1 (rs11615) may serve as a potential pharmacogenetic marker of response to FLOT, supporting further research in personalized treatment strategies. Full article
(This article belongs to the Special Issue Functional and Regulatory Cancer Genomics)
Show Figures

Figure 1

Back to TopTop